CliffBio
small molecule

LORAZEPAM

LORAZEPAM

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameLORAZEPAM
Active ingredientLORAZEPAM
Strength2MG/ML
Dosage formCONCENTRATE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2013
Marketing statusDISCN

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.